[HTML][HTML] Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
CN Pierre, LE Adams, JS Higgins, K Anasti… - PLOS …, 2024 - journals.plos.org
Antibodies perform both neutralizing and non-neutralizing effector functions that protect
against certain pathogen-induced diseases. A human antibody directed at the SARS-CoV-2 …
against certain pathogen-induced diseases. A human antibody directed at the SARS-CoV-2 …
Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections
Z Zhuang, J Zhuo, Y Yuan, Z Chen, S Zhang, A Zhu… - Vaccines, 2024 - mdpi.com
Despite significant strides in vaccine research and the availability of vaccines for many
infectious diseases, the threat posed by both known and emerging infectious diseases …
infectious diseases, the threat posed by both known and emerging infectious diseases …
[HTML][HTML] Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
S Slamanig, I González-Domínguez, LA Chang… - …, 2024 - thelancet.com
Background In order to prevent the emergence and spread of future variants of concern of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing vaccines …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing vaccines …
Compartment-Specific Antibody Correlates of Protection to SARS-CoV-2 Omicron in Macaques
Antibodies represent a primary mediator of protection against respiratory viruses. Serum
neutralizing antibodies (NAbs) are often considered a primary correlate of protection …
neutralizing antibodies (NAbs) are often considered a primary correlate of protection …
[图书][B] From vaccination to infection: mechanistic studies of immune responses to SARS-CoV-2
K Lenart - 2024 - openarchive.ki.se
The emergence of a novel coronavirus, SARS-CoV-2, sparked a global health crisis, leading
to the COVID-19 pandemic. Development and deployment of vaccines against COVID-19 …
to the COVID-19 pandemic. Development and deployment of vaccines against COVID-19 …